About CMS

Current Location:About CMS > Corporate Honors
2018

CMS acquired all assets of the Chinese market for six injection varieties such as gemcitabine (four of which are anti-tumor and two of which are antibiotics)

CMS acquired all relevant assets of China and Asia designated countries of ACT017 and subsequent products of France company Acticor Biotech

CMS had the right to obtain exclusive, permanent, transferable and sublicensable R&D, registration, production and commercialization of the existing products of Israel company Can-Fite BioPharma CF101 and CF102 in China.

CMS acquired all relevant assets of China, Korea, North Korea and Mongolia of the leading product BB2603 from British company Blueberry Therapeutics Limited

CMS signed an asset transfer framework agreement for portable neuromodulation stimulator (PoNS) from Helius Medical Technologies, USA

CMS and US company Neurelis, Inc signed an asset transfer framework agreement for products NRL-1 and/or extension lines

CMS has acquired right to develop exclusive, permanent, transferable and sub-licensable R&D and commercial products in China and Asian designated countries from company VAXIMM AG's current pharmaceutical products (currently VXM01).

2017

Traumakine, an innovative drug owned by CMS (including assets for the China market and other designated areas as well as certain intellectual properties), has completed the patients recruitment for phase III INTEREST clinical trials

CMS has acquired certain assets in Destiny Pharma plc.’s product portfolio (XF-73、XF-70、DPD-207) in China and other Asian countries (excluding Japan)

CMS had a total of 36.83% equity interest of Tibet Pharmaceutical after completing the capital increase and continued to be its single largest shareholder

2016

CMS obtained the exclusive right to commercialize Plendil in China and CMS’s affiliated company Tibet Pharmaceutical acquired Imdur’s global assets (US market excluded)

2015

CMS acquired Exclusive Sale Right and Promotion Right of NuoDiKang from Tibet Pharmaceutical

CMS acquired Xili Pharmaceutical and obtained the Exclusive Sale and Marketing Rights for DanShenTong in China

CMS signed Assets Purchase Agreement with DKSHI to purchase assets of Combizym and Hirudoid in designated countries or regions

CMS was included in the Hang Seng China (Hong Kong-listed) 100 Index

CMS donated drugs and monies valued around RMB 2 million as emergency reliefs for the 2015 Tianjin Explosion

2014

CMS acquired all assets of Beacon Pharmaceuticals Limited’s product Succinylated Gelatin Injection related to the Chinese market

CMS purchased all assets related to the Augentropfen Stulln Mono Eye-drops for the Chinese market, meanwhile, the two parties reached into consensus to assist Pharma Stulln GmbH in expanding production capacity

CMS had a total of 26.61% equity interest of Tibet Pharmaceutical after the acquisition and became the single largest shareholder of it

CMS was included in the Morgan Stanley Capital International (MSCI) China Index

CMS purchased assets related to Novartis’s products Lamisil®Tablet and Parlodel®Tablet for the Chinese market

CMS purchased assets related to NORGINE’s product MOVICOL® for the Chinese market

2012

CMS purchased the Exclusive Sales Rights of Yin Lian Qing Gan Ke Li and other products in China for 20 years from Beijing Yadong Biopharmaceutical Co., Ltd

2011

CMS successfully acquired 100% equity interest of Tianjin Precede Medical Trade Development Co., Ltd. (officially renamed Tianjin Kangzhe Pharmaceutical Technology Development Co., Ltd., on 24 October 2011)

2010

CMS was successfully listed on the Main Board of SEHK (Stock Code: 867)

CMS obtained the Exclusive Agency and Distribution Rights for Bioflor in China

2008

CMS obtained the exclusive rights to promote and sell XinHuoSu, Cystistat and Salofalk in China

2006

CMS obtained the exclusive rights to promote and sell Augentropfen Stulln Mono Eye-drops and GanFuLe in China

2002

CMS obtained the exclusive rights to promote and sell Deanxit and Ursofalk in China

1998

CMS’s affiliated company obtained the exclusive rights to promote and sell Ursofalk in China

1997

CMS’s affiliated company obtained the exclusive rights to promote and sell Deanxit in China

1995

Group Established

2021

Won the "Best Pharmaceutical and Medical Company" Award from Golden Hong Kong Listed Companies

Won the “Best Information Disclosure Award of China Excellent IR”

Recognized as the “Honored Company” in 2021 by the Institutional Investors Magazine and won top three of honors including "Best CEO", "Best CFO", "Best IR Professional", "Best IR Program", and "Best ESG"

Listed on “China’s Top 500 Listed Companies by Market Value”

Ranked No.7 on "CSR Ranking of Pharmaceutical Enterprises in 2020" by Southern Weekly

2020

Included in “CNI Nanshan 50 Index”

Won the "The Best Hong Kong Stock-Connect Company" Award from Golden Hong Kong Listed Companies

Included in “Hang Seng Stock-Connect Biotech 50 Index”

Tibet Kangzhe Pharmaceutical Development Co., Ltd. won the "Excellent Development and Opening up Enterprise Award in Lhasa Economic and Technological Development Zone”

Included in "Hang Seng Large-Mid Cap (Investable) Index"

Shenzhen Kangzhe was Selected for "2020 Shenzhen Top 500 Enterprises"

Tibet Kangzhe has been Honored with “2019 Top 20 Private Enterprises of Tibet Autonomous Region”

MSCI-ESG Rating Upgraded to "AA", Reaching the Global Leading Level

Won the “Excellent Pharmaceutical Industry Award” of “Top 100 Hong Kong Listed Companies”

Shenzhen Kangzhe was awarded "Top 100 Corporate Taxpayers in Nanshan District" in 2020

2019

Won Golden Hong Kong Listed Companies Award of "The Most Valuable Pharmaceutical Listing Company" for three consecutive years

Honored with three awards including “2019 Top 10 Listed Companies with the Highest Investment Value in China Pharmaceutical Industry”, “Top 100 Innovative Pharmaceutical Enterprises in China”, and “Benchmarking Enterprises in Pharmaceutical Industry at the 70th Anniversary of PRC Founding” at the China Healthcare Summit of Entrepreneurs, Scientists and Investors

Ms. Chen Yanling was awarded the “Best CFO of Hong Kong Listed Companies” in the Gelonghui’s First Best Listed Companies of Greater China Award

2018

Won Golden Hong Kong Listed Companies Award of "The Most Valuable Pharmaceutical Listing Company" for two consecutive years

Successfully selected as “The Most Attractive Hong Kong Stock-Connect Companies for Institutional Investors”

Awarded the title of "Honored Enterprise" in 2018 by the Institutional Investors Magazine; Ms. Chen Yanling was awarded "The Best Chief Financial Officer in Asia"by the Institutional Investors Magazine for the seventh time in a row

Won the Golden Wing Award of "Hong Kong Stock-Connect Company with the Most Substantial Growth Potential" held by the Securities Times

Received the award of "Shenzhen's Most Potential Employer in 2018"

2017

Once again won BIVA “Best Investment Value Award for Listed Companies”

Won Golden Hong Kong Listed Companies Award of "The Most Valuable Pharmaceutical Listing Company"  

Shenzhen Kangzhe was awarded “Top 100 Enterprises in Shenzhen” in 2017

Shenzhen Kangzhe was awarded “2017 Top 100 Corporate Taxpayers“ in Nanshan District

Awarded the “All-Asia Most Honored Company”; Mr. Lam Kong was awarded “All-Asia Best CEO” by Institutional Investor Magazine in 2017; Ms. Chen Yanling was awarded “All-Asia Best CFO” by Institutional Investor Magazine in 2017; CMS’s investor relation team was awarded “All-Asia Best Investor Relations” in 2017

2016

Shenzhen Kangzhe was awarded “Top 100 Enterprises in Shenzhen” in 2016

Awarded “The Listed Company with the Best Investment Value”

Awarded “Top Ten Health Innovation Enterprises” by M.D. Weekly

Ms. Chen Yanling was awarded “All-Asia Best CFO” by Institutional Investor Magazine in 2016 for the fifth time consecutively

2015

Shenzhen Kangzhe was awarded “Top 100 Corporate Taxpayers in Nanshan District” in 2015

Shenzhen Kangzhe was awarded “Top 100 Enterprises in Shenzhen” in 2015

Awarded The Best Investor Relations in the Greater China Awards Ceremony held by Investors Relation (IR) Magazine

Ms. Chen Yanling was awarded “All-Asia Best CFO” by Institutional Investor Magazine in 2015 for the fourth time consecutively

Tianjing Kangzhe was awarded “2014 Top 20 Science and Technology Small Giant Enterprise Certificate (Tianjin Development Zone)” for two consecutive years as well as the honorary title of “Top 100 Enterprises in Tianjing Development Zone”

Ranked on the list of Forbes on the “Best Enterprises Under a Billion” in 2015

Won the “Best Listed Company” award

2014

Included in the Morgan Stanley Capital International (MSCI) China Index

Included in the MSCI Emerging Markets Index

Mr. Lam Kong was awarded “All-Asia Best CEO” by Institutional Investor Magazine in 2014; Ms. Chen Yanling was awarded “All-Asia Best CFO” by Institutional Investor Magazine in 2014

Ranked in the list of Forbes on “Asia’s Best 200 Enterprises Under a Billion” in 2014

Won the “The Listed Company with the Best Information Disclosure”of the “2014 China Securities Golden Bauhinia Award” held by Ta Kung Pao

Shenzhen Kangzhe won “Top 100 Enterprises in Shenzhen” in 2014

2013

Ms. Chen Yanling was awarded “All-Asia Best CFO” by Institutional Investor Magazine in 2013

Shenzhen Kangzhe won “Top 100 Enterprises in Shenzhen” in 2013

2012

Ranked in the list of Forbes on “China's Best Up-And-Coming Businesses” in 2012

Ms. Chen Yanling was awarded “All-Asia Best CFO” by Institutional Investor Magazine in 2012

Tianjin Kangzhe was recognized as “Tianjin High-tech Enterprise”

Tianjin Kangzhe was awarded Certificate of “Tianjin A-grade Corporate Taxpayer”

2011

Ranked in the list of Forbes on “China's Best Up-And-Coming Businesses” in 2011

Shenzhen Kangzhe was awarded “Top 100 Enterprises in Shenzhen” in 2011

2010

Ranked in the list of Forbes on “China's Best Up-And-Coming Businesses” in 2010

Shenzhen Kangzhe was awarded “Top 100 Enterprises in Shenzhen” in 2010

Shenzhen Kangzhe was awarded “Top 100 Corporate Taxpayers in Nanshan District” in 2010

2009

Shenzhen Kangzhe was awarded “Top 100 Enterprises in Shenzhen” in 2009

Shenzhen Kangzhe was awarded “Top 100 Innovative Small and Medium Enterprises in Shenzhen” in 2009

Shenzhen Kangzhe was awarded "Top 100 Corporate Taxpayers in Nanshan District" in 2009

2008

Ranked in the list of Forbes on “Asia’s Best 200 Enterprises Under a Billion” in 2008

Shenzhen Kangzhe was selected as "Leading Enterprises in Independent Innovative Industry"

Shenzhen Kangzhe was awarded "Top 100 Corporate Taxpayers in Nanshan District" in 2008

2004

Shenzhen Kangzhe was awarded “Top 100 Corporate Taxpayers” and “Top 100 Private Enterprise” of Futian district in 2004

Shenzhen Kangzhe was awarded “Top 50 Private Enterprise of Shenzhen”

2003

Shenzhen Kangzhe was awarded “Top 100 Corporate Taxpayers” and “Top 100 Private Enterprise” of Futian district in 2003

2002

Shenzhen Kangzhe was awarded “Top 100 Corporate Taxpayers” and “Top 100 Private Enterprise” of Futian district in 2002